ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,242,000 | -28.8% | 414,277 | -19.4% | 0.00% | -25.0% |
| Q2 2023 | $15,798,000 | +18.0% | 513,898 | +38.3% | 0.00% | 0.0% |
| Q1 2023 | $13,387,000 | -7.7% | 371,549 | +1.2% | 0.00% | 0.0% |
| Q4 2022 | $14,508,000 | -2.4% | 367,116 | -0.8% | 0.00% | -20.0% |
| Q3 2022 | $14,872,000 | -4.0% | 370,133 | +0.4% | 0.01% | 0.0% |
| Q2 2022 | $15,491,000 | -19.2% | 368,492 | -25.1% | 0.01% | 0.0% |
| Q1 2022 | $19,174,000 | +7.7% | 492,142 | +10.2% | 0.01% | +25.0% |
| Q4 2021 | $17,802,000 | +16.4% | 446,712 | +5.5% | 0.00% | 0.0% |
| Q3 2021 | $15,297,000 | +5.2% | 423,262 | +19.3% | 0.00% | 0.0% |
| Q2 2021 | $14,539,000 | +150.6% | 354,735 | +166.8% | 0.00% | +100.0% |
| Q1 2021 | $5,801,000 | +901.9% | 132,964 | +1050.4% | 0.00% | – |
| Q4 2020 | $579,000 | +103.9% | 11,558 | +72.2% | 0.00% | – |
| Q3 2020 | $284,000 | +67.1% | 6,712 | +92.5% | 0.00% | – |
| Q2 2020 | $170,000 | – | 3,487 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |